Reply: Is high-dose glucocorticoid beneficial in COVID-19?
- PMID: 33602862
- PMCID: PMC7898159
- DOI: 10.1183/13993003.00324-2021
Reply: Is high-dose glucocorticoid beneficial in COVID-19?
Abstract
Our clinical trial supports the beneficial use of a high dose of methylprednisolone for the treatment of severe COVID-19 patients.
Conflict of interest statement
Conflict of interest: M. Edalatifard has nothing to disclose. Conflict of interest: M. Akhtari has nothing to disclose. Conflict of interest: M. Salehi has nothing to disclose. Conflict of interest: E. Farhadi has nothing to disclose. Conflict of interest: A. Jamshidi has nothing to disclose. Conflict of interest: M. Mahmoudi has nothing to disclose. Conflict of interest: A. Rostamian has nothing to disclose.
Comment on
-
Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.Eur Respir J. 2020 Dec 24;56(6):2002808. doi: 10.1183/13993003.02808-2020. Print 2020 Dec. Eur Respir J. 2020. PMID: 32943404 Free PMC article. Clinical Trial.
References
-
- World Health Organization . Clinical Management of COVID-19: living guidance. Geneva, World Health Organization, 2020. www.who.int/publications/i/item/clinical-management-of-covid-19.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical